BACKGROUND: The Vancouver Coastal Health Authority will initiate North America's first sanctioned safer injecting facility, as a pilot project, on Sept. 15, 2003. The analyses presented here were conducted to estimate the potential use of safer injecting facilities by local illicit injection drug users (IDUs) and to evaluate the potential impact of newly established Health Canada restrictions and current police activities on the use of the proposed facility. METHODS: During April and May 2003, we recruited active IDUs in Vancouver's Downtown Eastside to participate in a feasibility study. We used descriptive and univariate statistics to determine potential use of a safer injecting facility and to explore factors associated with willingness to use such a facility with and without federal restrictions and police presence. RESULTS: Overall, 458 street-recruited IDUs completed an interviewer-administered survey, of whom 422 (92%) reported a willingness to use a safer injecting facility. Those expressing willingness were more likely to inject in public (odds ratio [OR] 3.9, 95% confidence interval [CI] 1.9-8.0). When the restrictions in the Health Canada guidelines were considered, only 144 (31%) participants were willing to use a safer injecting facility. IDUs who inject alone were more likely (OR 1.8, 95% CI 1.0-3.1) and women were less likely (OR 0.6, 95% CI 0.4-0.9) to be willing to use a safer injecting facility operating under these restrictions. Only 103 (22%) of the participants said they would be willing to use a safer injecting facility if police were stationed near the entrance. INTERPRETATION: Most IDUs participating in this study expressed a willingness to use a safer injecting facility. However, willingness declined substantially when the IDUs were asked about using a facility operating under selected Health Canada restrictions and in the event that police were stationed near the entrance.
BACKGROUND: The Vancouver Coastal Health Authority will initiate North America's first sanctioned safer injecting facility, as a pilot project, on Sept. 15, 2003. The analyses presented here were conducted to estimate the potential use of safer injecting facilities by local illicit injection drug users (IDUs) and to evaluate the potential impact of newly established Health Canada restrictions and current police activities on the use of the proposed facility. METHODS: During April and May 2003, we recruited active IDUs in Vancouver's Downtown Eastside to participate in a feasibility study. We used descriptive and univariate statistics to determine potential use of a safer injecting facility and to explore factors associated with willingness to use such a facility with and without federal restrictions and police presence. RESULTS: Overall, 458 street-recruited IDUs completed an interviewer-administered survey, of whom 422 (92%) reported a willingness to use a safer injecting facility. Those expressing willingness were more likely to inject in public (odds ratio [OR] 3.9, 95% confidence interval [CI] 1.9-8.0). When the restrictions in the Health Canada guidelines were considered, only 144 (31%) participants were willing to use a safer injecting facility. IDUs who inject alone were more likely (OR 1.8, 95% CI 1.0-3.1) and women were less likely (OR 0.6, 95% CI 0.4-0.9) to be willing to use a safer injecting facility operating under these restrictions. Only 103 (22%) of the participants said they would be willing to use a safer injecting facility if police were stationed near the entrance. INTERPRETATION: Most IDUs participating in this study expressed a willingness to use a safer injecting facility. However, willingness declined substantially when the IDUs were asked about using a facility operating under selected Health Canada restrictions and in the event that police were stationed near the entrance.
Authors: D C Des Jarlais; D Paone; J Milliken; C F Turner; H Miller; J Gribble; Q Shi; H Hagan; S R Friedman Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: Evan Wood; Thomas Kerr; Will Small; Jim Jones; Martin T Schechter; Mark W Tyndall Journal: J Acquir Immune Defic Syndr Date: 2003-09-01 Impact factor: 3.731
Authors: S R Friedman; D C Des Jarlais; C E Sterk; J L Sotheran; S Tross; J Woods; M Sufian; A Abdul-Quader Journal: Milbank Q Date: 1990 Impact factor: 4.911
Authors: Patricia M Spittal; Kevin J P Craib; Evan Wood; Nancy Laliberté; Kathy Li; Mark W Tyndall; Michael V O'Shaughnessy; Martin T Schechter Journal: CMAJ Date: 2002-04-02 Impact factor: 8.262
Authors: Evan Wood; Patricia M Spittal; Thomas Kerr; Will Small; Mark W Tyndall; Michael V O'Shaughnessy; Martin T Schechter Journal: Can J Public Health Date: 2003 Sep-Oct
Authors: Evan Wood; Thomas Kerr; Patricia M Spittal; Kathy Li; Will Small; Mark W Tyndall; Robert S Hogg; Michael V O'Shaughnessy; Martin T Schechter Journal: J Acquir Immune Defic Syndr Date: 2003-01-01 Impact factor: 3.731
Authors: Evan Wood; Patricia M Spittal; Will Small; Thomas Kerr; Kathy Li; Robert S Hogg; Mark W Tyndall; Julio S G Montaner; Martin T Schechter Journal: CMAJ Date: 2004-05-11 Impact factor: 8.262
Authors: Evan Wood; Thomas Kerr; Will Small; Kathy Li; David C Marsh; Julio S G Montaner; Mark W Tyndall Journal: CMAJ Date: 2004-09-28 Impact factor: 8.262
Authors: Kora DeBeck; Thomas Kerr; Calvin Lai; Jane Buxton; Julio Montaner; Evan Wood Journal: Am J Drug Alcohol Abuse Date: 2011-08-11 Impact factor: 3.829
Authors: Evan Wood; Mark W Tyndall; Zhenguo Qui; Ruth Zhang; Julio S G Montaner; Thomas Kerr Journal: Am J Public Health Date: 2006-03-29 Impact factor: 9.308